291 related articles for article (PubMed ID: 11407654)
21. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
Cappa M; Grossi A; Borrelli P; Ghigo E; Bellone J; Benedetti S; Carta D; Loche S
Horm Res; 1993; 39(1-2):51-5. PubMed ID: 8406340
[TBL] [Abstract][Full Text] [Related]
22. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
Popovic V; Leal A; Micic D; Koppeschaar HP; Torres E; Paramo C; Obradovic S; Dieguez C; Casanueva FF
Lancet; 2000 Sep; 356(9236):1137-42. PubMed ID: 11030292
[TBL] [Abstract][Full Text] [Related]
23. Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.
Beccaria L; Benzi F; Sanzari A; Bosio L; Brambilla P; Chiumello G
J Endocrinol Invest; 1996 Nov; 19(10):687-92. PubMed ID: 9007701
[TBL] [Abstract][Full Text] [Related]
24. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone response to standard provocative stimuli and combined tests in very young children with Prader-Willi syndrome.
Di Giorgio G; Grugni G; Fintini D; Bocchini S; Spera S; Cuttini M; Cappa M; Crinò A
Horm Res Paediatr; 2014; 81(3):189-95. PubMed ID: 24503962
[TBL] [Abstract][Full Text] [Related]
27. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
[TBL] [Abstract][Full Text] [Related]
29. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
[TBL] [Abstract][Full Text] [Related]
30. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
[TBL] [Abstract][Full Text] [Related]
31. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
Guzzaloni G; Grugni G; Morabito F
Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
[TBL] [Abstract][Full Text] [Related]
32. Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.
Guzzaloni G; Grugni G; Morabito F
J Endocrinol Invest; 1999 May; 22(5):360-8. PubMed ID: 10401710
[TBL] [Abstract][Full Text] [Related]
33. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity.
Goldstone AP; Unmehopa UA; Swaab DF
Clin Endocrinol (Oxf); 2003 Jun; 58(6):743-55. PubMed ID: 12780752
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers CY; Granda-Ayala R
Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
Hoeck HC; Vestergaard P; Jakobsen PE; Falhof J; Laurberg P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
[TBL] [Abstract][Full Text] [Related]
37. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
38. Physical activity or food intake prior to testing did not affect the reproducibility of GH secretion elicited by GH releasing hormone plus GH-releasing hexapeptide in normal adult subjects.
Popovic V; Pekic S; Simic M; Damjanovic S; Micic D; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 2002 Jan; 56(1):89-94. PubMed ID: 11849251
[TBL] [Abstract][Full Text] [Related]
39. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
Beccaria L; Bosio L; Sanzari A; Aimaretti G; Ghigo E; Chiumello G
J Pediatr Endocrinol Metab; 1996; 9(6):577-83. PubMed ID: 9004172
[TBL] [Abstract][Full Text] [Related]
40. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
